[CAS NO. 1150701-66-8] GSK1940029
PRODUCTS SPECIFICATIONS [1150701-66-8]
DESCRIPTION [1150701-66-8]
Overview
| MDL | - |
|---|---|
| Molecular Weight | 391.25 |
| Molecular Formula | C18H16Cl2N4O2 |
| SMILES | ClC(C=CC(CN1N=NC(C(NC2=CC=C(CO)C=C2)=O)=C1C)=C3)=C3Cl |
2 Publications Citing Use of MCE
Summary
GSK1940029 (SCD inhibitor 1) is a stearoyl-coa desaturase ( SCD ) inhibitor extracted from patent WO/2009060053 A1, compound example 16.
IC50 & Target
Stearoyl-CoA Desaturase (SCD) [1]
In Vitro
GSK1940029 (SCD inhibitor 1) is a stearoyl-coa desaturase (SCD), which can be used to treat and/or preventing various diseases, including those mediated by SCD enzyme, such as diseases related to elevated lipid levels, cardiovascular disease, diabetes, obesity, metabolic syndrome, skin disorders such as acne, diseases or conditions related to cancer and the treatment of symptoms linked to the production of the amyloid plaque-forming Aβ42 peptide such as Alzheimer's disease [1] .
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date | Phase |
|---|---|---|---|---|
| NCT01938482 | GlaxoSmithKline |
Acne Vulgaris
|
October 31, 2013 | Phase 1 |
| NCT01984801 | GlaxoSmithKline |
Acne Vulgaris
|
October 14, 2013 | Phase 1 |
Appearance
Solid
Shipping
Room temperature in continental US; may vary elsewhere.
Storage
| Powder | -20°C | 3 years |
|---|---|---|
| 4°C | 2 years | |
| In solvent | -80°C | 6 months |
| -20°C | 1 month |
Solvent & Solubility
DMSO : ≥ 32 mg/mL ( 81.79 mM )
* "≥" means soluble, but saturation unknown.
Stock Solutions
| Concentration Solvent Mass | 1 mg | 5 mg | 10 mg |
|---|
| 1 mM | 2.5559 mL | 12.7796 mL | 25.5591 mL |
| 5 mM | 0.5112 mL | 2.5559 mL | 5.1118 mL |
| 10 mM | 0.2556 mL | 1.2780 mL | 2.5559 mL |